|
|
|
|
| LEADER |
03626nam a22006255i 4500 |
| 001 |
24000 |
| 003 |
DE-He213 |
| 005 |
20151204144317.0 |
| 007 |
cr nn 008mamaa |
| 008 |
140528s2013 xxk| s |||| 0|eng d |
| 020 |
# |
# |
|a 9781907673948
|9 978-1-907673-94-8
|
| 024 |
7 |
# |
|a 10.1007/978-1-907673-94-8
|2 doi
|
| 050 |
# |
4 |
|a RC254-282
|
| 072 |
# |
7 |
|a MJCL
|2 bicssc
|
| 072 |
# |
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 100 |
1 |
# |
|a Alvarez, Ricardo H.
|e author.
|
| 245 |
1 |
0 |
|a Handbook of HER2-targeted agents in breast cancer
|c by Ricardo H Alvarez, Javier Cortés, Leticia De Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas.
|h [electronic resource] /
|
| 264 |
# |
1 |
|a Tarporley :
|b Springer Healthcare Ltd. :
|b Imprint: Springer Healthcare,
|c 2013.
|
| 300 |
# |
# |
|a XI, 96 p. 13 illus.
|b online resource.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
# |
# |
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
# |
|a Introduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer.
|
| 520 |
# |
# |
|a Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15́Ơ 25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
|
| 650 |
# |
0 |
|a Medicine.
|
| 650 |
# |
0 |
|a General practice (Medicine).
|
| 650 |
# |
0 |
|a Internal medicine.
|
| 650 |
# |
0 |
|a Oncology.
|
| 650 |
# |
0 |
|a Primary care (Medicine).
|
| 650 |
# |
0 |
|a Pharmacotherapy.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Primary Care Medicine.
|
| 650 |
2 |
4 |
|a General Practice / Family Medicine.
|
| 650 |
2 |
4 |
|a Internal Medicine.
|
| 650 |
2 |
4 |
|a Pharmacotherapy.
|
| 700 |
1 |
# |
|a Cortés, Javier.
|e author.
|
| 700 |
1 |
# |
|a Mattos-Arruda, Leticia De.
|e author.
|
| 700 |
1 |
# |
|a Falzon, Mary.
|e author.
|
| 700 |
1 |
# |
|a Fasolo, Angelica.
|e author.
|
| 700 |
1 |
# |
|a Gandy, Michael.
|e author.
|
| 700 |
1 |
# |
|a Gianni, Luca.
|e author.
|
| 700 |
1 |
# |
|a Harbeck, Nadia.
|e author.
|
| 700 |
1 |
# |
|a Piccart, Martine.
|e author.
|
| 700 |
1 |
# |
|a Zambelli, Stefania.
|e author.
|
| 700 |
1 |
# |
|a Zardavas, Dimitrios.
|e author.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781907673931
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-907673-94-8
|z View fulltext via EzAccess
|
| 912 |
# |
# |
|a ZDB-2-SME
|
| 950 |
# |
# |
|a Medicine (Springer-11650)
|